Non-Exclusive Pharmaceutical Discount Agreement for Formoterol/Glycopyrronium/Budesonid (ATC R03AL11) via Open-House Model
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Formoterol/Glycopyrronium/Budesonid (ATC-Code nach WHO: R03AL11)
Opportunity Score
Why this score?
Opportunity
55 / 100
Complexity
40 / 100
Risk factors
Actual demand is unknown and depends on prescription behavior, patient numbers, and pharmacy stocking. No minimum volum...
The buyer may terminate the open-house process early if exclusive discount agreements are concluded, typically 8-12 mon...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jun 30, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Supply of pharmaceutical product Formoterol/Glycopyrronium/Budesonid (ATC R03AL11)
- Non-exclusive discount agreement under §130a Abs. 8 SGB V
Show full summary
Non-exclusive pharmaceutical discount agreement (Rabattvertrag) for the active ingredient Formoterol/Glycopyrronium/Budesonid (ATC R03AL11) via an Open-House model. The agreement is open to all eligible pharmaceutical entrepreneurs, with no guaranteed volume or exclusivity. Contract ends 30.06.2027. First submission deadline: 02.06.2025; further deadlines as per attached schedule.
Risks
Actual demand is unknown and depends on prescription behavior, patient numbers, and pharmacy stocking. No minimum volum...
The buyer may terminate the open-house process early if exclusive discount agreements are concluded, typically 8-12 mon...
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) per §4 Abs.18 AMG
Eligibility
- Must submit declarations: exclusion grounds and Russia sanctions
Administrative
- Communication and submission via DTVP portal
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-Exclusive Pharmaceutical Discount Agreement for Formoterol/Glycopyrronium/Budesonid (ATC R03AL11) via Open-House Model
Supply of pharmaceutical product under a non-exclusive discount agreement. No guaranteed minimum volume. Contract duration until 30.06.2027.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Formoterol/Glycopyrronium/Budesonid (ATC-Code nach WHO: R03AL11)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 277852-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
55 / 100
Complexity
40 / 100
Risk factors
Actual demand is unknown and depends on prescription behavior, patient numbers, and pharmacy stocking. No minimum volum...
The buyer may terminate the open-house process early if exclusive discount agreements are concluded, typically 8-12 mon...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications